This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on Web of Science (12)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

GEORGE A. HIGGINS, JR., MD; THOMAS FLYNN, MD; JOHN GILLESPIE, MD

AMA Arch Surg. 1964;88(4):627-632.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

In any type of medical therapy careful consideration of possible harmful effects of the therapeutic agent being used is essential—primum non nocere has long been one of the basic precepts of medical practice. One of the primary concerns in establishing the various surgical cancer chemotherapy cooperative groups was the hazard of administering cancer chemotherapy drugs to patients potentially cured of cancer by the operative procedure. One of the factors leading to the choice of mechlorethamine hydrochloride (nitrogen mustard) and thio-tepa (triethyelene thiophosphoramide) as the anticancer agents to be used in the Veterans Administration Adjuvant Cancer Chemotherapy Study was the considerable clinical experience which had accumulated in the usage and toxic manifestation of these drugs.⁸ The dosage regimen selected to be administered to patients undergoing excisional surgery was essentially the same as that used in numerous patients being treated for far advanced visceral cancer or for lymphoma. For . . . [Full Text PDF of this Article]

Author Affiliations
WASHINGTON, DC

From the Veterans Administration Hospital and the Department of Surgery, The Georgetown University Medical School.

Footnotes
Read before the 71st Annual Session of the Western Surgical Association, Galveston, Tex, Nov 21-23, 1963.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?